Identification of DNA methylation biomarkers in imatinib-resistant chronic myeloid leukemia cells

Ren In You, Ching Liang Ho, Hsiu Man Hung, Yu Fung Hsieh, Jy Ciou Ju, Tsu Yi Chao

研究成果: 雜誌貢獻文章同行評審

3 引文 斯高帕斯(Scopus)


Drug resistance is an obstacle to successful cancer treatment. In hematological neoplasms, such as chronic myelogenous leukemia (CML), drug resistance is often associated with gene hypermethylation and loss of function. An imatinib-resistant subclone of CML-like K562 (K562-R) was used as a model to study the role of hypermethylation in drug resistance. K562-R was selected by culturing cells with increasing concentrations of imatinib, ranging from 0.2-5 μM. A DNA methylation microarray was performed on the K562-R and parental K562 cells, and selected gene expression levels were confirmed using real-time polymerase chain reaction. The methylation level was significantly increased and the gene expression level significantly was decreased for MLH1, RPRM, FEM1B, and THAP2 in K562-R cells compared with parental K562 cells. Exposing K562-R cells to methylation inhibitors, such as 5-azacytidine (AzaC) and trichostatin A (TSA), reduced imatinib resistance. Our approach of using a drug-limiting dilution model followed by the use of a methylation microarray was able to identify methylation biomarkers for drug resistance. Specifically, MLH1, RPRM, FEM1B, and THAP2 might be potential epigenetic targets of imatinib resistance. Further understanding the methylation domain and epigenetic regulation machinery of these biomarkers will help researchers find potential effective therapeutic strategies that could be used to overcome drug resistance in CML patients.

頁(從 - 到)12-15
期刊Genomic Medicine, Biomarkers, and Health Sciences
出版狀態已發佈 - 3月 2012

ASJC Scopus subject areas

  • 生物醫學工程
  • 生物化學、遺傳與分子生物學 (全部)
  • 藥物發現


深入研究「Identification of DNA methylation biomarkers in imatinib-resistant chronic myeloid leukemia cells」主題。共同形成了獨特的指紋。